Adolescent bariatric series reported major weight loss

What happened

An open-access retrospective study published July 2, 2026 in Obesity Surgery reported outcomes for 76 patients ages 10 to 25 who had metabolic and bariatric surgery at a single accredited Louisiana center between January 2020 and March 2025. The work came from the Metamor Institute, Pennington Biomedical Research Center, and Our Lady of the Lake Regional Medical Center in Baton Rouge, with Philip Schauer among the senior authors.

The cohort was 80 percent female with a mean age of 22.6 years, a mean preoperative weight of 136.8 kilograms, and a mean BMI of 49.4. Just over half were African American and 75 percent had Medicaid coverage, with only 18 percent on commercial insurance. Baseline disease was common: type 2 diabetes in 32 percent, biopsy-confirmed MASH in 33 percent, GERD in 38 percent, hypertension in 18 percent, sleep apnea in 17 percent, and dyslipidemia in 16 percent.

Operations were laparoscopic in every case: sleeve gastrectomy in 59 percent, Roux-en-Y gastric bypass in 37 percent, and SADI-S in 4 percent. Mean operative time was about 107 minutes and the mean hospital stay was 1.5 days. Four patients had a 30-day complication, including three requiring reoperation under anesthesia; 5 percent were readmitted and 4 percent required reoperation overall. There were no deaths at 30 days or one year.

Mean percentage total weight loss was 29.4 percent at one year, 29.7 percent at two years, and 32.0 percent at three to five years among patients still followed. At last follow-up, 94 percent of those measured had lost at least 15 percent of their body weight. Among the 16 diabetes patients with available follow-up data, 15 achieved remission off diabetes medications, and mean HbA1c fell from 6.2 to 5.3 percent. Hypertension improved in 8 of 12 patients measured and GERD improved or resolved in 7 of 11.

What it means

The cohort's makeup is the story behind the numbers. A majority-Black, heavily Medicaid-insured Southern population looks little like the mostly privately insured, lower-BMI adolescents in the large multicenter registry studies that shape pediatric metabolic surgery guidance. Severe baseline BMI near 50 means the average percentage losses translate into very large absolute weight changes, roughly 40 kilograms for the average patient.

Safety figures sit comfortably against reference standards. The 5 percent 30-day complication rate and zero mortality are consistent with the Teen-LABS experience and with adult benchmarks cited in the paper, which supports the position that carefully selected young adults can undergo these operations safely outside elite referral centers.

For families considering surgery, the practical signals are the speed of recovery, a day and a half in hospital on average, and the depth of diabetes response, 15 of 16 followed patients off diabetes medication. The paper also notes six of the 24 diabetes patients were on GLP-1 drugs before surgery and only one remained on one afterward, an early hint about how surgery changes medication needs.

What it does not mean

This was a single-center retrospective review with a modest sample size and a mean follow-up of only 16 months. Follow-up attrition is the dominant limitation: only 69 percent of patients had one-year data, 57 percent two-year data, and 50 percent data at three to five years, so the longest-term results describe the half of the cohort that returned. The authors state plainly that the findings should be read as exploratory rather than definitive.

Only about 12 percent of the cohort was under 18, so despite the adolescent framing these results mostly reflect patients 18 to 25 and cannot be generalized to young teenagers specifically. MASH resolution could not be assessed because no repeat liver biopsies were performed. Retrospective design means selection effects cannot be excluded: healthier or more adherent patients may be both more likely to return for follow-up and to do well. None of this establishes that surgery outperforms medication or lifestyle treatment head to head, and treatment decisions belong with a multidisciplinary clinical team.